Table 2.
Clinical and Pathological Characteristics of Prostate Tissues Adjacent to Tumor
| Relapse status | None (n = 28) | Long PSADT (n = 13) | Short PSADT (n = 8) |
|---|---|---|---|
| Mean age (P = 0.554) | 55 | 57.69 | 56.06 |
| Cancer stage (P = 0.541) | |||
| pT1 | 3 (6.1) | 0 (0) | 0 (0) |
| pT2 | 11 (22.4) | 4 (8.2) | 3 (6.1) |
| pT3a | 7 (14.3) | 6 (12.2) | 1 (2.0) |
| pT3b | 7 (14.3) | 3 (6.1) | 4 (8.2) |
| Gleason grade (P = 0.9849) | |||
| 5 | 1 (2.0) | 0 (0) | 0 (0) |
| 6 | 7 (14.3) | 3 (6.1) | 2 (4.1) |
| 7 | 16 (32.7) | 7 (14.3) | 5 (10.2) |
| 8–10 | 4 (8.2) | 3 (6.1) | 1 (2.0) |
| Race (P = 0.08387) | |||
| Black | 0 | 1 | 0 |
| Unknown | 6 | 0 | 0 |
| White | 22 | 12 | 8 |
| Median follow-up (months) | 155 | 149 | 29.205 |
| Median time to progression (months) | NA | 54.6 | 3.09 |
| Median PSADT (months) | NA | 26.9 | 2.46 |
| Mean preoperative PSA (P = 0.074) | 8.23 | 12.98 | 6.3 |
Data are given as number (percentage) of the 49 samples unless otherwise indicated.
NA, not applicable.